Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04408092 · ClinicalTrials.gov registry record · Early Phase 1
Study of the Effect of GM-CSF on Macrophages in Ependymoma
A Early Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT04408092: Completed Early Phase 1 study, sponsored by University of Colorado, Denver.
NCT04408092 is a Early Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04408092, a Early Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma
Primary Outcome
Outcome measure is met if cell count is \>50 AIF1+ microglia per high power field (40x)
Interventions
- DRUG Granulocyte Macrophage Colony Stimulation Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-06-25 |
| Est. Completion | 2023-07-21 |
| Phase | Early Phase 1 |
What the finished NCT04408092 record still lists
NCT04408092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Granulocyte Macrophage Colony Stimulation Factor is the first listed.
NCT04408092 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04408092 about?
NCT04408092 is a clinical study titled "Study of the Effect of GM-CSF on Macrophages in Ependymoma". This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients wi...
What is the current status of trial NCT04408092?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2013-06-25. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT04408092?
The interventions under investigation include: Granulocyte Macrophage Colony Stimulation Factor (DRUG).
Who is sponsoring clinical trial NCT04408092?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04408092's enrollment target sits among peer trials
6 1845th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI